Eyenovia Stock Price, News & Analysis

Eyenovia, Inc. (NASDAQ: EYEN), now operating under the corporate name Hyperion DeFi, Inc., represents a distinctive combination of ophthalmic technology and digital asset treasury management. According to recent company disclosures and SEC filings, the business describes itself as a pioneering digital ophthalmic technology company and the first U.S. publicly listed company to build a long-term strategic treasury of HYPE, the native token of the Hyperliquid blockchain.

Under its ophthalmic technology focus, Eyenovia is developing and commercializing products based on its proprietary Optejet topical ophthalmic medication dispensing platform. Company materials state that the Optejet device is designed to deliver a low-volume, targeted columnar spray of ophthalmic liquid, which may improve ease of use, safety, tolerability and treatment compliance compared with traditional eye drops. The Optejet User Filled Device (UFD) is described as being designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products, and is especially useful in chronic front-of-the-eye diseases where consistent dosing and patient adherence are important.

In its commercial portfolio, Eyenovia reports that it markets clobetasol propionate ophthalmic suspension, 0.05% for post-surgical pain and inflammation and Mydcombi for mydriasis. The company’s disclosures emphasize that these offerings, together with the Optejet platform, are intended to provide advanced topical ophthalmic treatment options for patients and eye care providers.

Dual Focus: Ophthalmic Technology and HYPE Treasury

Alongside its ophthalmic activities, Eyenovia has adopted what it calls a cryptocurrency treasury reserve strategy centered on HYPE. Company filings and news releases describe Hyperliquid as a layer one blockchain engineered for transparent, high-frequency trading, with fully onchain perpetual futures and spot order books and support for decentralized financial applications via the HyperEVM smart contract platform.

Eyenovia states that it is building a long-term strategic treasury of HYPE to provide shareholders with simplified exposure to the Hyperliquid ecosystem. The company explains that shareholders may benefit from gradually compounding exposure to HYPE through native staking yield and additional revenues generated from HYPE’s on-chain utility. As part of this strategy, Eyenovia has entered into a private placement to fund the acquisition of HYPE tokens and has launched a co-branded Hyperliquid validator in collaboration with Kinetiq, with infrastructure support from Pier Two.

According to the company’s supplemental business description filed with the SEC, running its own validator allows Eyenovia to access HYPE staking yield and contribute to network stability and security. The company also notes that staked HYPE can be delegated to user accounts, potentially reducing trading fees or increasing revenue share from referrals on Hyperliquid, which it views as additional revenue opportunities linked to its onchain engagement.

Corporate Name and Ticker Transition

An 8-K filing reports that on June 30, 2025, the company filed a Certificate of Amendment to change its name from Eyenovia, Inc. to Hyperion DeFi, Inc.. The amendment became effective on July 1, 2025. The same filing states that, as a result of the name change, the company anticipates that its common stock will cease trading under the ticker symbol “EYEN” and will begin trading under the new ticker symbol “HYPD” on the Nasdaq Capital Market effective July 3, 2025. The CUSIP for the common stock did not change in connection with the ticker change. The filing also notes that the name change does not affect the voting or other rights associated with the company’s common stock.

Optejet User Filled Device (UFD)

Company disclosures provide additional detail on the Optejet UFD. The device is described as an ergonomic, user-filled platform that enables horizontal drug delivery, removing the need to tilt the head back or squeeze a traditional dropper bottle. Eyenovia reports that the Optejet delivers a more physiologically appropriate volume of medication in the range of seven to ten microliters, compared with the larger volume typically delivered by standard eye drops. The company states that this lower volume can expose the ocular surface to less active ingredient and preservatives, potentially reducing ocular surface stress and systemic exposure.

In its SEC filing, Eyenovia notes that the Optejet’s non-protruding nozzle and self-closing shutter are designed to minimize contamination risk, and that clinical trials have shown a high rate of successful administration, with a majority of sprays accurately delivered on first attempt. The company links these characteristics to the potential for improved tolerability and adherence in chronic front-of-the-eye conditions.

Hyperliquid and the HYPE Token

In its risk factor and business overview supplement, the company describes Hyperliquid as a proof-of-stake layer one blockchain featuring a traditional order book model for non-custodial trading of digital asset perpetual futures and spot markets. It notes that Hyperliquid supports high transaction throughput and short block times, and that the HyperEVM enables permissionless decentralized applications.

The company explains that HYPE is the native token of Hyperliquid, used for staking, transaction fees on the HyperEVM, and as collateral in decentralized finance applications. Eyenovia highlights a mechanism by which trading fees on Hyperliquid are used to autonomously purchase and remove HYPE from circulation, and notes that a significant amount of HYPE has been removed from circulation through this process. It also notes that HYPE holders can delegate tokens to validators participating in the network’s HyperBFT consensus, earning staking rewards and participating in governance decisions such as listing or delisting markets.

Strategic Positioning

Across its public communications, the company presents itself as combining a digital ophthalmic technology platform with a digital asset treasury strategy. It emphasizes ongoing development of the Optejet UFD, including verification and validation activities aimed at supporting regulatory submissions, while simultaneously building and deploying a HYPE treasury and operating a validator on Hyperliquid.

According to its filings, Eyenovia views this dual focus as a way to pursue ophthalmic product opportunities while also engaging with the Hyperliquid ecosystem. The company’s disclosures indicate that it expects its HYPE holdings, staking activities, validator operations and potential onchain strategies such as lending and liquidity provisioning to form part of its broader business model as it transitions under the Hyperion DeFi, Inc. name and HYPD ticker.